PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

Overview of attention for article published in Frontiers in immunology, December 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 52 Dimensions

Readers on

mendeley: 32 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 50,094 followers.

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy https://t.co/qzoNyMU6fr https://t.co/PIRXWO0oeF

19 Dec 2022

Reply Repost Favourite

New Research: PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy: Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. Sorafenib monotherapy has been the standard of first-line… https://t.co/xX

19 Dec 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.